Aeglea BioTherapeutics

Aeglea BioTherapeutics is a clinical-stage biotechnology company focused on developing human enzyme therapeutics for rare metabolic diseases. The company engineers enzymes to create therapies that can modulate chemical imbalances in the body that are the cause of a variety of diseases.

Its main area of research is in amino acid metabolism, where it is developing treatments for patients with rare genetic conditions that affect their ability to process certain amino acids. The company's business model is centered on the research and development of novel drug candidates, which it then takes through the clinical trial process to gain regulatory approval. As a clinical-stage company, Aeglea BioTherapeutics does not yet have products on the market and its revenue is primarily derived from funding from investors and partnerships.

The company serves a niche market of patients with rare metabolic diseases, a segment of the pharmaceutical industry that has a high unmet medical need. Its main drug candidate, pegzilarginase, is being developed for the treatment of Arginase 1 Deficiency, a rare genetic disorder.

Keywords: biotechnology, enzyme therapeutics, rare metabolic diseases, amino acid metabolism, clinical-stage, pegzilarginase, Arginase 1 Deficiency, genetic disorders, drug development, biopharmaceuticals